Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 3/20 | 0.78 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.78 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.78 |
| ▸ | LMNA | P02545 | 2/20 | 0.67 |
| ▸ | MEN1 | O00255 | 4/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.64 |
| ▸ | HPGD | P15428 | 7/20 | 0.64 |
| ▸ | POLB | P06746 | 3/20 | 0.64 |
| ▸ | ATM | Q13315 | 1/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.62 |
| ▸ | RAB9A | P51151 | 1/20 | 0.62 |
| ▸ | PKM | P14618 | 3/20 | 0.58 |
| ▸ | MAPT | P10636 | 3/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4703104 | 0.95 | HTT (0.71) | HTTSMN1; SMN2ALOX15LMNAMEN1 | |
| SCHEMBL4700801 | 0.94 | HTT (0.69) | HTTSMN1; SMN2ALOX15LMNAMEN1 | |
| SCHEMBL5212645 | 0.92 | HPGD (0.68) | HTTSMN1; SMN2ALOX15LMNAMEN1 | |
| SCHEMBL243430 | 0.88 | SMN1; SMN2 (1.00) | HTTSMN1; SMN2ALOX15LMNAMEN1 | |
| SCHEMBL12046962 | 0.84 | LMNA (0.74) | HTTSMN1; SMN2ALOX15LMNAMEN1 | |
| SCHEMBL6645560 | 0.83 | SMN1; SMN2 (0.91) | HTTSMN1; SMN2ALOX15LMNAKMT2A | |
| SCHEMBL9641726 | 0.83 | SMN1; SMN2 (0.70) | HTTSMN1; SMN2ALOX15LMNAHPGD | |
| SCHEMBL5256099 | 0.82 | SMN1; SMN2 (0.70) | HTTSMN1; SMN2ALOX15LMNAMEN1 | |
| SCHEMBL25062713 | 0.82 | LMNA (0.67) | HTTSMN1; SMN2ALOX15LMNAMEN1 | |
| SCHEMBL77032 | 0.82 | KMT2A (0.68) | HTTSMN1; SMN2ALOX15MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060194821-A1 | Compounds inhibiting the aggregation of superoxide dismutase-1 | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2006-08-31 | — | — | US | claimed |
| WO-2010014554-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITION FOR THE TREATMENT OF COLLAPSING GLOMERULOPATHY AND OTHER GLOMERULAR DISEASE | GENZYME CORPORATION (US) | 2010-02-04 | — | — | WO | disclosed |
| EP-1853276-A2 | COMPOUNDS INHIBITING THE AGGREGATION OF SUPEROXIDE DISMUTASE-1 | The Brighamn and Women's Hospital, Inc. (US) | 2007-11-14 | — | — | EP | disclosed |
| EP-1363925-B8 | MACROLIDE ANTIBIOTICS | GLAXO GROUP LTD (GB) | 2007-04-25 | — | — | EP | disclosed |
| EP-1363925-B1 | MACROLIDE ANTIBIOTICS | GLAXO GROUP LTD (GB) | 2006-11-15 | — | — | EP | disclosed |
| US-20060211636-A1 | Macrolide Antibiotics | ALIHODZIC SULEJMAN | 2006-09-21 | — | — | US | disclosed |
| US-20060194821-A1 | Compounds inhibiting the aggregation of superoxide dismutase-1 | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2006-08-31 | — | — | US | disclosed |
| WO-2006089221-A2 | COMPOUNDS INHIBITING THE AGGREGATION OF SUPEROXIDE DISMUTASE-1 | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2006-08-24 | — | — | WO | disclosed |
| US-20050215495-A1 | Macrolide antibiotics | ALIHODZIC SULEJMAN | 2005-09-29 | — | — | US | disclosed |
| US-20040077557-A1 | Macrolide antibiotics | GLAXO GROUP LIMITED (GB) | 2004-04-22 | — | — | US | disclosed |
| EP-1363925-A1 | MACROLIDE ANTIBIOTICS | GLAXO GROUP LIMITED (GB) | 2003-11-26 | — | — | EP | disclosed |
| WO-2002050091-A1 | MACROLIDE ANTIBIOTICS | GLAXO GROUP LIMITED (GB) | 2002-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050215495-A1 | Macrolide antibiotics | IL1R1, MRPL12, RPS21 | HTT 3482/4885SMN1; SMN2 3554/4885ALOX15 2590/4885 |
| US-20060211636-A1 | Macrolide Antibiotics | IL1R1, MRPL12, RPS21 | HTT 3482/4885SMN1; SMN2 3554/4885ALOX15 2590/4885 |
| US-20060194821-A1 | Compounds inhibiting the aggregation of superoxide dismutase-1 | SOD1, SOD3, CAT | HTT 46/4885SMN1; SMN2 8/4885ALOX15 1506/4885 |
| US-20040077557-A1 | Macrolide antibiotics | MALT1, MRPL21, IL1R1 | HTT 3592/4885SMN1; SMN2 3041/4885ALOX15 2244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.